Trial Profile
A one year, multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride (E2020) in subjects with mild cognitive impairment.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Feb 2014
Price :
$35
*
At a glance
- Drugs Donepezil (Primary)
- Indications Mild cognitive impairment
- Focus Adverse reactions; Therapeutic Use
- 05 May 2009 Primary endpoint 'Assessment scale scores' has not been met.
- 05 May 2009 Primary endpoint 'Alzheimer's Disease Assessment Scale' has been met.
- 22 Oct 2005 New trial record.